Sapropterin (BH4) challenge in phenylketonuria: Responder or non-responder?

Sapropterin dihydrochloride, the synthetic form of tetrahydrobiopterin (BH4), is an established pharmacological treatment for a subset of patients with phenylalanine hydroxylase (PAH) deficiency. Yet the clinically simple question of whether a patient is a "responder" or "non-responder" remains difficult to answer in a uniform way. Since the first description of BH4-responsive PAH deficiency, challenge protocols have varied substantially, ranging from short 4-8 h loading tests to 24-48 h protocols, 72 h to 7-day approaches, and treatment trials lasting several weeks or months. These protocols differ in dose, duration, sampling schedule, dietary conditions, baseline phenylalanine (Phe) concentration, use of Phe loading, and response definition. European, American, and Japanese guidance also differ in target ranges and in how responsiveness is confirmed. The widely used criterion of at least 30% reduction in blood Phe is practical for short biochemical testing, but it may be insufficient in patients who are already well controlled on diet, in slow responders, in infants or preschool children in whom BH4 bioavailability may be lower, and in patients whose main benefit is increased daily dietary Phe tolerance rather than further Phe reduction. Recent European guidance distinguishes potential sapropterin responsiveness from long-term responsiveness, defining the latter by increased natural protein intake and/or improved biochemical control within the recommended therapeutic target range. Japanese guidance adds an important Asian perspective by recommending BH4 administration tests for all hyperphenylalaninemia/phenylketonuria (PKU) cases rather than relying only on phenotype or blood Phe level, and recent Japanese data suggest that age and baseline Phe may influence blood biopterin peaks and the risk of false-negative tests. This narrative review summarizes the historical development, biological rationale, clinical evidence, geographical variation, genotype-specific considerations, and practical limitations of BH4/sapropterin responsiveness testing in PKU. We propose a pragmatic responder/non-responder framework based on three linked dimensions: blood Phe reduction, increase in daily dietary Phe tolerance, and maintenance of blood Phe within age-, pregnancy-, and guideline-specific therapeutic ranges. A responder is best defined as a patient who demonstrates either reproducible biochemical response or clinically meaningful therapeutic benefit, while a non-responder is a patient who demonstrates neither under adequate testing conditions. Evidence from extended Dutch testing further supports using 7-day protocols selectively when 48 h results are borderline or clinically discordant, while avoiding a simple 20% threshold because of false-positive risk.